138 related articles for article (PubMed ID: 22788125)
1. Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity.
Karan D; Van Veldhuizen P
Immunotherapy; 2012 Jun; 4(6):577-80. PubMed ID: 22788125
[TBL] [Abstract][Full Text] [Related]
2. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
[TBL] [Abstract][Full Text] [Related]
3. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
Simons JW; Sacks N
Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of immunotherapy in prostate cancer.
Gerritsen WR
Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Garcia JA; Dreicer R
Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
[TBL] [Abstract][Full Text] [Related]
7. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
Dong B; Minze LJ; Xue W; Chen W
Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in immunotherapy for the treatment of prostate cancer.
Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
[TBL] [Abstract][Full Text] [Related]
9. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.
Santegoets SJ; Stam AG; Lougheed SM; Gall H; Jooss K; Sacks N; Hege K; Lowy I; Scheper RJ; Gerritsen WR; van den Eertwegh AJ; de Gruijl TD
J Immunother Cancer; 2014; 2():31. PubMed ID: 26196012
[TBL] [Abstract][Full Text] [Related]
10. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW
Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721
[TBL] [Abstract][Full Text] [Related]
12. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
Higano CS; Corman JM; Smith DC; Centeno AS; Steidle CP; Gittleman M; Simons JW; Sacks N; Aimi J; Small EJ
Cancer; 2008 Sep; 113(5):975-84. PubMed ID: 18646045
[TBL] [Abstract][Full Text] [Related]
13. [Current status and prospects of immunotherapy for castration-resistant prostate cancer].
Yatsuda J; Eto M
Nihon Rinsho; 2014 Dec; 72(12):2174-8. PubMed ID: 25518354
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.
Quinn DI; Shore ND; Egawa S; Gerritsen WR; Fizazi K
Urol Oncol; 2015 May; 33(5):245-60. PubMed ID: 25575714
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer immunotherapy.
McNeel DG
Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.
Reimers MA; Slane KE; Pachynski RK
Curr Urol Rep; 2019 Sep; 20(10):64. PubMed ID: 31482315
[TBL] [Abstract][Full Text] [Related]
17. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.
De Remigis A; de Gruijl TD; Uram JN; Tzou SC; Iwama S; Talor MV; Armstrong TD; Santegoets SJ; Slovin SF; Zheng L; Laheru DA; Jaffee EM; Gerritsen WR; van den Eertwegh AJ; Le DT; Caturegli P
Int J Cancer; 2015 Jan; 136(1):127-37. PubMed ID: 24832153
[TBL] [Abstract][Full Text] [Related]
18. New and emerging agents for the treatment of castration-resistant prostate cancer.
Higano CS; Crawford ED
Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
[TBL] [Abstract][Full Text] [Related]
19. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.
Hege KM; Jooss K; Pardoll D
Int Rev Immunol; 2006; 25(5-6):321-52. PubMed ID: 17169779
[TBL] [Abstract][Full Text] [Related]
20. Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.
Saad F; Miller K
Urology; 2015 May; 85(5):976-986. PubMed ID: 25709051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
